胃食管反流病患者内镜阴性后上消化道癌发病率与死亡率
该研究基于丹麦、芬兰、挪威和瑞典1979至2018年新诊断胃食管反流病患者队列,评估内镜阴性暴露与上消化道癌发病及死亡的关系。结果显示内镜阴性者上消化道癌风险降低55%(HR 0.45,95%CI 0.43-0.48),死亡风险降低61%(HR 0.39,95%CI 0.37-0.42),且风险降低分别持续5年和至少10年。
要点
- 胃食管反流病患者内镜阴性后上消化道癌风险降低55%。
- 内镜阴性者上消化道癌死亡风险降低61%。
- 发病风险降低持续5年,死亡风险降低至少持续10年。
核心结论
- 胃食管反流病患者内镜阴性与大而上消化道癌发病率及死亡率长期降低相关。
主要发现
- 随访期间5324例(0.5%)发生上消化道癌,4465例(0.4%)死于上消化道癌。
- 内镜阴性者上消化道癌风险较未内镜者降低55%(HR 0.45;95%CI 0.43-0.48)。
- 2008年及以后内镜阴性者上消化道癌风险降低更明显(HR 0.34;95%CI 0.30-0.38),且在不同性别和年龄组中稳定。
- 内镜阴性者上消化道癌死亡风险降低61%(校正HR 0.39;95%CI 0.37-0.42)。
- 内镜阴性后发病风险降低持续5年,死亡风险降低至少持续10年。
临床怎么用
- 对胃食管反流病患者,内镜阴性结果可提示上消化道癌发病和死亡风险长期降低,可能有助于风险分层与随访策略制定。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND AIMS: Gastroesophageal reflux disease (GERD) is associated with an increased risk of cancer of the upper gastrointestinal tract. This study aimed to assess whether and to what extent a negative upper endoscopy in patients with GERD is associated with decreased incidence and mortality in upper gastrointestinal cancer (ie, esophageal, gastric, or duodenal cancer). METHODS: We conducted a population-based cohort study of all patients with newly diagnosed GERD between July 1, 1979 and December 31, 2018 in Denmark, Finland, Norway, and Sweden. The exposure, negative upper endoscopy, was examined as a time-varying exposure, where participants contributed unexposed person-time from GERD diagnosis until screened and exposed person-time from the negative upper endoscopy. The incidence and mortality in upper gastrointestinal cancer were assessed using parametric flexible models, providing adjusted hazard ratios (HRs) with 95% confidence intervals (CIs). RESULTS: Among 1,062,740 patients with GERD (median age 58 years; 52% were women) followed for a mean of 7.0 person-years, 5324 (0.5%) developed upper gastrointestinal cancer and 4465 (0.4%) died from such cancer. Patients who had a negative upper endoscopy had a 55% decreased risk of upper gastrointestinal cancer compared with those who did not undergo endoscopy (HR, 0.45; 95% CI, 0.43-0.48), a decrease that was more pronounced during more recent years (HR, 0.34; 95% CI, 0.30-0.38 from 2008 onward), and was otherwise stable across sex and age groups. The corresponding reduction in upper gastrointestinal mortality among patients with upper endoscopy was 61% (adjusted HR, 0.39; 95% CI, 0.37-0.42). The risk reduction after a negative upper endoscopy in incidence and mortality lasted for 5 and at least 10 years, respectively. CONCLUSIONS: Negative upper endoscopy is associated with strong and long-lasting decreases in incidence and mortality in upper gastrointestinal cancer in patients with GERD.
引用
- Holmberg D, Santoni G, von Euler-Chelpin MC, et al. Incidence and Mortality in Upper Gastrointestinal Cancer After Negative Endoscopy for Gastroesophageal Reflux Disease. Gastroenterology. 2021. PMID: 34627859. doi:10.1053/j.gastro.2021.10.003
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。